Stay updated with breaking news from Daniel Spratt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Artificial intelligence was used to develop a predictive biomarker to identify patients with intermediate-risk prostate cancer who would benefit from adding androgen deprivation therapy to radiotherapy.
A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence.
Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.
SAN FRANCISCO--(BUSINESS WIRE)--Jun 29, 2023--
Delayed testing and less access to tailored, advanced treatments drive higher mortality rates for Black men with prostate cancer compared to other men.